NIP
CLVS

Nicholas Investment Partners’s Clovis Oncology, Inc. CLVS Stock Holding History

Nicholas Investment Partners’s Portfolio CLVS Stock Details CLVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-114,460
Closed -$2.84M – 242
2019
Q1 		$2.84M Buy
114,460
+35,723
+45% +$896K 0.25% 139
2018
Q4 		$1.41M Buy
+78,737
New +$1.61M 0.15% 190
2017
Q4 		– Sell
-24,917
Closed -$2.05M – 281
2017
Q3 		$2.05M Buy
24,917
+6,440
+35% +$511K 0.14% 209
2017
Q2 		$1.73M Sell
18,477
-9,387
-34% -$574K 0.12% 217
2017
Q1 		$1.77M Buy
+27,864
New +$1.69M 0.13% 221
2015
Q4 		– Sell
-45,136
Closed -$4.15M – 335
2015
Q3 		$4.15M Buy
45,136
+10,073
+29% +$872K 0.3% 133
2015
Q2 		$3.08M Sell
35,063
-11,249
-24% -$963K 0.2% 210
2015
Q1 		$3.44M Sell
46,312
-11,547
-20% -$815K 0.21% 201
2014
Q4 		$3.24M Buy
57,859
+5,743
+11% +$302K 0.2% 192
2014
Q3 		$2.36M Buy
52,116
+1,670
+3% +$69.8K 0.15% 221
2014
Q2 		$2.09M Buy
50,446
+3,017
+6% +$155K 0.12% 231
2014
Q1 		$3.29M Buy
+47,429
New +$3.48M 0.27% 123

Other funds holding CLVS

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

Nicholas Investment Partners's CLVS Position: Q2 2019 in Review

Nicholas Investment Partners sold out of Clovis Oncology, Inc. (CLVS) in Q2 2019, closing a stake of 114,460 shares — an estimated $2.84M sold.

Nicholas Investment Partners first reported a position in CLVS in Q1 2014 and held it in 12 quarters. The position peaked at $4.15M in Q3 2015. 167 funds tracked by Wall St. Rank hold CLVS as of Q2 2019.

  • Nicholas Investment Partners reported no remaining Clovis Oncology, Inc. position as of Q2 2019 after selling out during the quarter.
  • Nicholas Investment Partners sold 114,460 Clovis Oncology, Inc. shares in Q2 2019, an estimated $2.84M.
  • Nicholas Investment Partners first reported a position in Clovis Oncology, Inc. in Q1 2014 and held it in 12 quarters.
  • Nicholas Investment Partners's Clovis Oncology, Inc. position peaked at $4.15M in Q3 2015.
  • 167 funds tracked by Wall St. Rank held Clovis Oncology, Inc. as of Q2 2019.

Based on Nicholas Investment Partners's 13F filing for Q2 2019, filed 9 Aug 2019.